# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that members of...
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price ...
Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $31 price target.
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target f...
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of...
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price...
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price...
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target f...